Moderna R&D day: $1 billion in cost cuts, 10 product launches
WEBSep 12, 2024 — Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid...
News Details - Moderna
WEBMar 26, 2024 — The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines.
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
WEBAugust 22, 2024. Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent...
News Details - Moderna
WEBMar 27, 2024 — Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development. Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024.
News Details - Moderna
WEBSep 11, 2023 — Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines expected to be available in the …
News Details - Moderna
WEBJan 8, 2024 — Moderna will enter the RSV market with a strong competitive profile as the only pre-filled syringe product available at the time of launch, along with robust efficacy data, a well-established safety and tolerability profile, and widespread consumer awareness and demand established in 2023.
Moderna, Pfizer say updated Covid vaccines were effective against ...
WEBSep 6, 2023 — Moderna, Pfizer say updated Covid vaccines were effective against highly mutated BA.2.86 variant in trials. New Covid vaccines from Moderna and Pfizer generated a strong immune response against...
FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better …
WEBSep 11, 2023 — As part of today’s actions, the bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States. Data Supporting the Updated mRNA COVID-19 Vaccines...
News Details - Moderna
WEBFeb 23, 2023 — Product sales for the fourth quarter of 2022 were $4.9 billion, a decrease of 30% compared to the same period in 2021, primarily driven by lower sales volume, compared to overall higher demand in the prior year and the related manufacturing ramp up in the fourth quarter of 2021.
Moderna says its RSV shot is 50% effective across a second season
WEBNEW YORK, June 26 (Reuters) - Moderna Inc (MRNA.O) respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.